Since the prevalence of AD and T2DM is on the rise and, notably, BDNF expression undergoes significant alterations in these pathological conditions, the development of novel treatments or utilizing already available ones, such as RSG, that target BDNF, its receptors and key signaling pathways is necessary [11,31,32,33,34]. Here, BDNF is linked to Alzheimer disease.